Abiopharma

🔍 AWM Investment Company, Inc. (Executive)

Company: 908 Devices Inc. (MASS)

Report Date: 2026-08-20

Detailed Transactions and Holdings:

• Sold 8,422 shares of Common Stock at $10.5246 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,821,351.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 41,578 shares of Common Stock at $10.6104 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,779,773.00 | transaction_form_type: 4 | Footnotes: F2, F1, F2, F2, F2

Footnotes:

• F1: This is a weighted average price.
• F2: AWM Investment Company, Inc., a Delaware Corporation (AWM), is the investment adviser to Special Situations Fund III QP, L.P. (SSFQP), Special Situations Cayman Fund, L.P. (CAY), Special Situations Private Equity Fund, L.P. (SSPE), Special Situations Technology Fund, L.P. (TECH) and Special Situations Technology Fund II, L.P. (TECH II and together with SSFQP, CAY, SSPE and TECH, the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 1,981,785 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 565,726 Shares held by CAY, 216,802 Shares held by SSPE, 338,137 Shares held by TECH and 1,677,323 Shares held by TECH II.
• F3: David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are the controlling principals of AWM. The reporting person disclaims beneficial ownership of the Shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.